1026MO A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors
Authors:
- 20 October 2023
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 34, S624